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Study objective: Novel evaluation of protective effect of tiotropium against induced dynamic
hyperinflation (DH) during metronome paced hyperventilation (MPH) in moderate COPD.
Methods: Prospective, randomized, double-blind, placebo control, crossover study. Lung func-
tion measured pre/post MPH at 30 breaths/min for 20 s in 29 (18M) COPD patients (GOLD Stage
2) age 70  9 yr (mean  SD) before and after 30 days of 18 mg tiotropium bromide vs placebo.
Lung CT scored for emphysema (ES).
Results: At baseline post 180 mg aerosolized albuterol sulfate, FEV1: 1.8  0.6 L (69  6%pred)
and 60% predicted in all, and 14 of 29 had FEV1 (L) 70% predicted with FEV1/FVC 58  8%.
After 29 days þ 23 h post tiotropium (trough) there was significant decrease only in FRC/TLC%
(p Z 0.04); after 30 days þ 2 h post tiotropium (peak) significant increase only in FEV1 (L)
(p Z 0.03) compared to placebo. Results post MPH induced DH at baseline and after 30 days
and 2 h post placebo or tiotropium were similar with decrease in IC 0.44  0.06 L
(p < 0.001). Correlation between ES and increased FEV1 (L) at peak tiotropium: r Z 0.19,
p Z 0.96 and decreased FRC/TLC% at trough tiotropium: r Z 0.26, p Z 0.36.
Conclusion: In moderate COPD, tiotropium did not reduce MPH induced DH and reduction in IC.
However, at peak tiotropium, there was significant bronchodilation in FEV1 (L) and at trough
a decrease in FRC/TLC% compared to placebo despite varying emphysema.
ª 2010 Elsevier Ltd. All rights reserved.y; MPH, metronome paced hyperventilation; DH, dynamic hyperinflation; FEV1, forced expiratory
idual capacity (L); TLC, total lung capacity (L).
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In moderate-to-severe COPD, FEV1 (L) % predicted corre-
lated poorly with clinical symptoms, exercise endurance
and response to bronchodilators. Alternatively, exercise
testing using constant or incremental cycle ergometry with
repeated measurements of inspiratory capacity (IC) has
been used to detect dynamic hyperinflation and evaluate
the response to bronchodilators.1
O’Donnell et al.2 have reported that Borg dyspneic
ratings and inspiratory capacity (IC) and endurance time
during submaximal cycle exercise testing were highly
reproducible and responsive to intervention in moderate-
to-severe COPD. Repeated measurements of IC during
exercise reflect changes in end-expiratory lung volume3e5
since total lung capacity remains constant after acute
bronchodilation and during exercise.6,7 Additionally, peak
values of inspiratory esophageal pressures used as a surro-
gate to estimate effort, are relatively constant and corre-
lated with breathing frequency at a given tidal volume
during multiple measurements of exercise IC.8,9
Reduction in IC during exercise, reflects dynamic hyper-
inflation (DH), and correlates with decreased exercise
endurance, and increased exertional dyspnea as well as
breathing frequency in COPD patients.5 We previously
reported the reduction in IC with metronome paced hyper-
ventilation (MPH), a relatively simple procedure, was similar
to decrease in IC following incremental symptom-limited
cycle ergometry in moderate-to-severe COPD.1 We also
noted 54 mg of inhaled ipratropium bromide (IB) failed to
blunt the decrease in IC.1 Previously, O0Donnell et al.2 noted
greater bronchodilation with much larger doses of nebulized
IB (500mg)whencompared tousual doses of inhaledalbuterol
sulfate in patients with COPD. Subsequently, using constant
cycle ergometry,O0Donnell et al.10 reported 18mg tiotropium
in patients with moderate-to-severe COPD improved IC,
exercise endurance and exertional dyspnea.
We previously reported in moderate-to-severe COPD
patients, tiotropium did not reduce DH induced by MPH.11
However, tiotropium induced bronchodilation with increase
in IC and decrease in end-expiratory lung volume was in part
compensatory and helped blunt dynamic hyperinflation.11
Moreover, tiotropium induced bronchodilation was inde-
pendent of the extent of lung CT scored emphysema in
moderate-to-severe COPD12 (GOLD Stage 2 and 3).13
The primary co-end points of the current novel study
were to evaluate: (1) trough and peak bronchodilator role
of tiotropium and (2) its ability to blunt MPH induced DH in
moderate GOLD Stage 2 COPD patients.13 The secondary
endpoints were to correlate primary physiologic responses
with varying extent of lung CT scored emphysema.14
Methods
We recruited 30 patients with smoking history >20 pack yr
with documented GOLD Stage 2 moderate COPD13 who were
clinically stable for at least 6weeks prior to the present study
and were not on oxygen or oral corticosteroid. This was
a prospective, randomized, double-blind, placebo control,
tiotropium crossover pilot study. History of wheezing and/or
responsiveness to aerosolized albuterol were not specificinclusion or exclusion criteria. Quality of life was graded
using established SGRQ criteria.15 Patients were instructed
to continueall their usualmedications, but towithhold short-
acting aerosolized beta2-agonists and/or ipratropium
bromide for 6 h and long-acting inhaled beta2-agonists (sal-
meterol or formoterol in all patients) for 48 h prior to initial
baseline testing. Volunteer patients for this study were
required to be off tiotropium for at least 4 weeks or be tio-
tropium naı¨ve prior to initiating the study. During the study
only short-acting aerosolized beta2-agonist was permitted.
Informedpatient consent and approval from theUniversity
of Toronto Medical Center, Ontario, Canada and Western
Institutional Review Board, Olympia, Washington was
obtained and this study was registered with NCT: 00569270.
Patients underwent lung function studies before and after
180 mg of aerosolized albuterol sulfate via MDI using tech-
niques and predictive values previously described in
detail.1,11,12 We used a spirometer (Model Vmax29), and
pressure-compensated flow plethysmograph (Model 6200),
both from SensorMedics, CareFusion, Yorba Linda, California.
Subsequently, on separate days, MPH was obtained
(Vmax29)usingpreviouslydescribedmethods1,11,12 in30COPD
patients. The goal was to achieve respiratory rate twice
baseline rate for 20 s, which was immediately followed by
sequential measurement of inspiratory capacity, expiratory
spirometry, andwithin30 splethysmographicmeasurementof
functional residual capacity. While no attempt was made to
control end tidal carbon dioxide, patients were coached to
maintain a respiratory rate synchronous with themetronome.
Near-constant dynamic tidal volumeduringMPHwas achieved
by having patients observe a graphic display of their breathing
pattern, however no attempt was made to blunt any increase
inventilation synchronouswith themetronome.Patientswere
studied at baseline and subsequently randomized to either 30
days of 18 mg tiotropium or 30 days of placebo and then
intervention crossed. Technicians who performed these
studies were blinded as were treating physicians and patients
to their medication. The technique for measuring inspiratory
capacity has been previously described.1,2,4
High-resolution thin-section CT of lung
High-resolution, thin-section scans of the lung were
obtained using a helical 64 slice multi detector-row CT
(Siemens Model Sensation 64, Malverne, PA) were obtained
in a subset of 19 patients. Images were obtained at 5 mm
collimation at intervals of 6 mm using 120 kVp and varying
mA dependent upon patient size. Reconstructured 1 mm
slices were obtained every 9 mm using window width of
850 HU and level of 600 HU with edge enhancing algo-
rithm. Images were scored by a radiologist (Mark J. Schein
MD, Department of Radiology, Lakewood Regional Medical
Center, Lakewood, California) 0 to 100, none to worst
emphysema, using picture templates, we previously vali-
dated using inflated whole lung specimens.14
Statistical analysis
Statistical analyses was performed by Fernando Camacho
(Damos Inc., Toronto, Ontario, Canada.) Since a crossover
design was used, the p-value for a given variable was
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response and with treatment including placebo and tio-
tropium, period and sequence as dependent variables. The
Mixed model properly takes into account that patients were
measured in both sequences of the study. The reported
p-values reported are the nominal values without Bonferroni
correction for multiple tests. Analysis was done using
a statistical softwarepackage (Sþ version forWindows,Tibco
Software, Palo Alto, California). Statistical significance was
p < 0.05. Based on our earlier study in patients with
moderate-to-severe COPD with GOLD13 Stage 2 and 3 we
calculated we needed a cohort of 29 patients with moderate
COPD consistent with GOLD13 Stage 2 for this pilot study. We
wanted to achieve a power of 80% at a significant alpha level
of 5% using projected sample inspiratory capacity of
2.23  0.5 L (mean  SD) post tiotropium compared to
baseline inspiratory capacity 2.0  0.5 L.
Results
Baseline studies (29 patients) (Table 1)
We initially studied 30 moderate GOLD Stage 2 COPD
patients but one patient violated the treatment protocol.
This report includes data from 29 (18 men) age 70  9 yr
(mean  SD) with past smoking history of 42  20 pack yr
(mean  SD). Twenty three patients were studied in Lake-
wood and 6 patients in Toronto and there were no signifi-
cant site differences in age, gender, and smoking history. At
baseline, routine lung function studies were similar in
patients from the two sites and the combined data is
described in Table 1 and is consistent with moderate GOLD
Stage 2 COPD.13 Following 180 mg of aerosolized albuterol
sulfate, FEV1 increased 13  12%. All patients had a post
180 mg albuterol by MDI, FEV1 (L) 60% predicted, and 14 of
29 had FEV1 (L) 70% predicted. Quality of life SGRQ score
ranged from 30e45.15Table 1 Baseline Results of Lung Function Studies
(mean  SD) in 29 Moderately Severe COPD13 Patients Age
70  9 years (mean  SD) prior to starting tiotropium.
Test Observed % Predicted
FVC (L) 2.9  1.2 86  17
FVC (L) post 180 mg
albuterol sulfate MDI
3.3  1.2 95  16
FEV1 (L) 1.6  0.6 61  8
FEV1 (L) post 180 mg
albuterol sulfate MDI
1.8  0.6 69  6
FEV1/FVC (%) 56  8
SGaw Lps/cmH2O/L 0.10  0.08
FRC (L) 3.9  0.8 138  29
RV (L) 2.9  0.1 131  37
TLC (L) 5.9  1.3 109  16
DLCOSB (ml/min/mmHg) 14  5 69  23
FVC Z forced vital capacity; FEV1 Z forced expiratory volume
in 1 s; FRC Z functional residual capacity; RV Z residual
volume; SGawZ specific airway conductance; TLCZ total lung
capacity; DLCOSB Z single-breath diffusing capacity. Predicted
values were previously described.1,11,12Primary end point: bronchodilator response after
30 days of tiotropium versus placebo (29 patients)
(Table 2)
After 18 mg of inhaled tiotropium daily for 30 days, the
changes in lung function studies at 1 h pre-dose (trough)
and 2 h post tiotropium dose (peak) appear in Table 2.
There was a significant (p Z 0.04) decrease only in FRC/
TLC% at trough, and increase in FEV1 (L) at peak tiotropium,
compared to placebo. Baseline FEV1 was 1.6  0.6 L, and it
increased 0.08  0.03 L, pZ 0.03 above placebo at 2 h post
dose. No significant changes were noted in total lung
capacity. In this crossover placebo/drug study, there was no
variable effect of treatment period and sequence.
Co-primary end point: metronome paced
hyperventilation (mph) induced dynamic
hyperinflation (dh) at baseline and after tiotropium
versus placebo (29 patients) (Table 3)
Following MPH there was a significant decrease in IC (L) at
baseline as reported in Table 3. Resting respiratory rate was
15  0.6 bpm (mean  SE) and post 20 s MPH it was
31  0.2 bpm, p < 0.0001, whereas resting tidal volume was
0.90  0.04 L and post 20 s MPH it was 0.76  0.04 L,
pZ 0.001. Resting IC was 2.09  0.83 L and post 20 s MPH it
was 1.76  0.07, p < 0.0001. There was no change in total
lung capacity. The magnitude of the decrease in IC corre-
lated modestly with decrease in tidal volume during MPH
(Spearman rho Z 0.45, p Z 0.0003).
After 30 days and 2 h post placebo, as well as after 30
days and 2 h post tiotropium, following MPH, the magnitude
of the changes in IC, respiratory rate, and tidal volume
were similar to baseline MPH induced DH results prior to
initiation of tiotropium (see Table 3).Table 2 Net change in lung function studies (mean  SE)
from baseline to trough (1 h) and peak (þ2 h) after 30 days
of tiotropium versus placebo in 29 moderate COPD patients.
Variable Mean difference
of tiotropium
minus placebo
SE t value p-value
Peak FEV1 (L) 0.08 0.03 2.33 0.027
Peak FRC (L) 0.08 0.08 1.02 0.318
Peak FVC (L) 0.10 0.05 1.83 0.078
Peak IC 0.12 0.03 1.91 0.067
Peak FRC/TLC% 0.01 0.03 0.51 0.615
Peak TLC (L) 0.13 0.12 1.00 0.325
Trough FEV1 (L) 0.02 0.03 0.96 0.345
Trough FRC (L) 0.17 0.09 1.90 0.068
Trough FVC (L) 0.03 0.05 0.55 0.589
Trough IC (L) 0.00 0.03 0.10 0.922
Trough FRC/TLC% 0.02 0.01 2.18 0.038
Trough TLC (L) 0.13 0.09 1.47 0.15
Same as Table 1.
After 29 days of tiotropium, compared to placebo, mean
changes in lung function parameters from baseline were
significant at 23 h (trough) for decrease in FRC/TLC% and 30
days plus 2 h post (peak) tiotropium for increase in FEV1 (L).
Table 3 Decrease in inspiratory capacity (IC) (mean  SE)
(L) following metronome paced hyperventilation induced
dynamic hyperinflation at baseline and post 30 days plus 2 h
of 18 mg tiotropium and post 30 days plus 2 h of placebo.
Change in TLC (L) is increase.
Test Change Time p-value
IC (L) 0.303  0.05 Baseline <0.0001
IC (L) 0.321  0.06 2 h post placebo <0.0001
IC (L) 0.439  0.06 2 h post tiotropium <0.0001
TLC (L) 0.05  0.0 Baseline, post placebo
and tiotropium
ns
Same as Tables 1 and 2.
There was no significant difference (p Z 0.12) between
decrease in IC following MPH induced DH at 2 h post placebo
versus 2 h post tiotropium. The p-value refers to the decrease in
IC (L) following MPH induced DH under varying study conditions
compared to resting IC.
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induced bronchodilation and extent of lung ct
scored emphysema (19 patients)
There was no correlation between high-resolution thin-
section lung CT scored extent of emphysema14 obtained in
19 patients and magnitude of increase in FEV1 (L) from
baseline to peak tiotropium (Spearman rho Z 0.19,
p Z 0.96) or decrease in FRC/TLC% at trough tiotropium
(Spearman rho Z 0.26, p Z 0.36).
Co-secondary end point: correlation between
decrease in inspiratory capacity post mph induced
dh and extent of lung ct scored emphysema
(19 patients)
Following MPH induced DH the decrease in IC did not
significantly correlate with high-resolution thin-section
lung CT scored extent of emphysema14 obtained in 19
patients (Spearman rho Z 0.20, p Z 0.4).
Discussion
Twenty-nine GOLD Stage 2, moderate COPD patients13 with
varying lung CT scored emphysema, completed a prospec-
tive, randomized, double-blind, placebo control, tio-
tropium crossover study. There was a significant decrease
from baseline in FRC/TLC% at trough and increase from
baseline in FEV1 (L) at peak tiotropium after 30 days,
compared to placebo arm. Furthermore, there was no
correlation between bronchodilation and extent of lung CT
scored emphysema. The current observations in moderate
COPD with GOLD13 Stage 2 patients with post albuterol FEV1
69  6% (mean  SD) predicted extend our previous results
in moderate-to-severe COPD, GOLD13 Stage 2 and 3 patients
with FEV1 63  6% predicted.11,12
Metronome paced hyperventilation (MPH) at twice
resting respiratory rate for 20 s to induce dynamic hyper-
inflation (DH) resulted in similar significant decrease in
inspiratory capacity (IC) in tiotropium versus placebo.
Furthermore, the decrease in IC was irrespective of theextent of lung CT scored emphysema, similar to our
previous observations in moderate-to-severe GOLD Stage 3
COPD.11,12 However, since tiotropium is a potent broncho-
dilator, there was a significant increase in peak FEV1 (L) and
decrease in trough FRC/TLC% compared to baseline. This
would help blunt the subsequent dyspneic and physiologic
challenge of MPH induced DH, by increasing exercise time,
as reported by O’Donnell et al.10 and Maltais et al.16 using
constant-load cycle ergometry.
The rationale to measure IC during exercise is that
among all variables studied, changes in IC (baseline and
peak exercise) not only showed good reproducibility, but
correlated best with changes in Borg dyspnea scale.2,3,15
Furthermore, since previously TLC did not change during
exercise1,6,7,11,12 as well as in the present study, any
increase in IC must reflect a decrease in dynamic hyperin-
flation in peripheral airways.
It is important to compare our current and prior results11
before and after tiotropium intervention during MPH
induced DH. The mean increase in FEV1 post 30 days plus 2 h
of tiotropium in the present study was 170 cc (78 cc above
placebo); and in our previous study post 30 days and 1.5 h
was 150 cc11 compared to results in other studies of 220 cc
post 42 days plus 1.3 h10 and 260 cc post 42 days plus 1.3 h
tiotropium.16 At similar time thresholds as above, in the
current study, the mean increase in IC was 150 cc; and
previously 180 cc11 compared to 250 cc10 and 220 cc.16 The
decreased magnitude of our current and past response11
compared to previous studies10,16 may be related to
moderate expiratory airflow limitation at baseline.
In the current study, the mean  SE decrease in IC imme-
diately following MPHwas 303 50 cc at baseline; 321 60 cc
post 30 days plus 2 h of placebo; and 439 60 cc post 30 days
plus 2 h tiotropium. In our previous study11 IC decrease was
370  40 cc at baseline and 350  30 cc post 1.5 h tiotropium
for 30 days. This compares to mean decrease in IC following
constant-load ergometry of 410 cc at both baseline and post
tioropium10 and 410 cc at baseline versus 490 cc post tio-
tropium.16 In above studies10e12,16 themagnitude of decrease
in IC following MPH induced DH and constant-load ergometry
was similar pre and post tiotropium. However, because of
tiotropium induced bronchodilation and reduction in resting
operational lung volumes both at rest and during exercise
(increased IC), patients noted improvement in exertional
dyspnea and exercise endurance.10,16 These and other physi-
ologic results17e19 support the observation of improved clin-
ical outcomes in bothmoderate and severe, GOLD Stage 2 and
3 COPD patients on long-term tiotropium.20
As emphasized in our previous study12 normal resting
airway smooth muscle tone is mediated primarily by the
parasympathetic cholinergic system21,22 via post ganglionic
acetylcholine on three muscarinic subtype receptors: M1, M2,
and especially M3.
23 Tiotropium achieves bronchodilation in
COPD safely through antagonism of the contractile effects of
normal or increased cholinergic innervation24e27 through
prolonged inhibitionofM3-receptors in large and small airways
leading to smooth muscle relaxation.21,23,28,29 Furthermore,
in alveolarwalls onlyM1-receptors are present.
28 Current FEV1
(L) andFRC/TLC%observations reinforceour initial IC results12
that the bronchodilator effect of tiotropium appears to be
independent of the extent of lung CT scored emphysema in
moderate and severe GOLD13 2 and 3 COPD phenotypes.
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increased cholinergic tone in COPD,24e26 would be incre-
mentally greater in critically narrowed small airways
compared to normals.30
The relative phenotypic contribution of emphysema
versus intrinsic small airway disease in COPD is highly
variable.12 The severity of lung CT scored emphysema
varies widely among COPD cohorts despite similar extent of
symptoms, response to aerosolized albuterol sulfate,
extent of expiratory airflow limitation and exercise toler-
ance.14,31e38 We have previously reported in a pathologic-
physiologic correlative study in 81 COPD patients with FEV1
<50% predicted that severe lung CT scored emphysema 60
(scale 0e100 worst)occurred only in 30%.14 Therefore, lung
CT scored extent of emphysema should not be used to
initiate or obviate tiotropium from the therapeutic regimen
for COPD. There have been numerous studies evaluating the
relationship between lung CT scoring techniques, especially
objective densitometry masks, to reproducibly quantify the
extent and distribution of emphysema and its functional
consequences.31e44 However, there has been only limited
corroboration with morphologic whole lung inflated speci-
mens.14,38,43 The visual lung CT technique to score
emphysema in the present study has been shown to have
a strong correlation with inflated whole lungs and provides
a reliable CT lung assessment of extent of morphologic
emphysema.14 The current lung CT results reinforce our
earlier lung CT similar observations in cohort of 29 COPD
patients.12 Additional similar studies with larger cohort size
will be needed to further evaluate COPD emphysema
phenotypes and efficacy of therapeutic intervention
including combinations of tiotropium, inhaled corticoste-
roids and long-acting beta2-agonists.
Results in the present study of 29 patients, demonstrate
significant improvement only in tiotropium trough FRC/TLC
% and peak FEV1. The limited number of patients in this
underpowered study was based on initial over-estimated IC
and can lead to a type 2 error. Had the same results been
observed in a study with double the number of patients
(nZ 58), more comparisons would have become significant
including increase in tiotropium peak FEV1 (L) (p Z 0.01);
FVC (L) (0.04); IC (L) (0.03); and decrease in trough FRC (L)
(p Z 0.03); and FRC/TLC% (p Z 0.02).
In summary, in GOLD Stage 2 moderate COPD, tiotropium
did not reduce MPH induced DH and reduction in IC despite
varying extent of lung CT scored emphysema. However,
despite an underpowered study, tiotropium induced
significant bronchodilation, with significant decrease in
trough FRC/TLC% and increase in peak FEV1 (L), indepen-
dent of varying lung CT emphysema. This should help buffer
the effects of exercise intolerance in these patients.Acknowledgement
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